Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Analyst Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PODD Stock 12 Month Forecast
Average Price Target
$326.07
▲(18.99% Upside)
| Highest Price Target$355.00 | Average Price Target$326.07 | Lowest Price Target$293.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
Reiterated
03/20/25
Wells Fargo
Reiterated
03/19/25
Bank of America Securities
Reiterated
03/19/25
RBC Capital
Initiated
03/05/25
Jefferies
Reiterated
03/03/25
William Blair
Reiterated
02/28/25
Bernstein
Reiterated
02/24/25
BTIG
Reiterated
02/24/25
Raymond James
Reiterated
02/21/25
Citi
Reiterated
02/21/25
Leerink Partners
$290→$314
Buy
14.58%
Upside
Reiterated
02/21/25
Robust Growth Prospects and Market Leadership Drive 'Buy' Rating for InsuletWe are reiterating our Outperform rating on PODD and increasing our PT to $314 (from $290) following the company's 4Q24 results and initial FY25 guidance. PODD reported a broad-based 4Q24 beat, with WW sales +3% vs. consensus (beat in both US and OUS) and non-GAAP GM +246 bps vs. consensus. Management highlighted several encouraging trends in 4Q24, including a growing mix of Type 2 diabetes (T2D) new customer starts (NCS), q/q and y/y NCS growth in both the US and OUS, and NCS growth in both Type 1 and T2D. PODD issued FY25 WW sales growth guidance of +16-20%, which brackets consensus and includes US Omnipod growth of +16-20% and OUS Omnipod growth of +22-26%, and FY25 GM guidance of 70.5%, which falls in line with consensus.
Stifel Nicolaus
$293
Hold
6.92%
Upside
Reiterated
02/21/25
Insulet (PODD) Receives a Hold from Stifel Nicolaus
Canaccord Genuity
$304→$324
Buy
18.23%
Upside
Reiterated
02/21/25
Insulet price target raised to $324 from $304 at CanaccordInsulet price target raised to $324 from $304 at Canaccord
Morgan Stanley
$317→$325
Buy
18.60%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)
Piper Sandler
$285→$310
Buy
13.12%
Upside
Reiterated
02/21/25
Insulet price target raised to $310 from $285 at Piper SandlerInsulet price target raised to $310 from $285 at Piper Sandler
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Reiterated
03/20/25
Wells Fargo
Reiterated
03/19/25
Bank of America Securities
Reiterated
03/19/25
RBC Capital
Initiated
03/05/25
Jefferies
Reiterated
03/03/25
William Blair
Reiterated
02/28/25
Bernstein
Reiterated
02/24/25
BTIG
Reiterated
02/24/25
Raymond James
Reiterated
02/21/25
Citi
Reiterated
02/21/25
Leerink Partners
$290→$314
Buy
14.58%
Upside
Reiterated
02/21/25
Robust Growth Prospects and Market Leadership Drive 'Buy' Rating for InsuletWe are reiterating our Outperform rating on PODD and increasing our PT to $314 (from $290) following the company's 4Q24 results and initial FY25 guidance. PODD reported a broad-based 4Q24 beat, with WW sales +3% vs. consensus (beat in both US and OUS) and non-GAAP GM +246 bps vs. consensus. Management highlighted several encouraging trends in 4Q24, including a growing mix of Type 2 diabetes (T2D) new customer starts (NCS), q/q and y/y NCS growth in both the US and OUS, and NCS growth in both Type 1 and T2D. PODD issued FY25 WW sales growth guidance of +16-20%, which brackets consensus and includes US Omnipod growth of +16-20% and OUS Omnipod growth of +22-26%, and FY25 GM guidance of 70.5%, which falls in line with consensus.
Stifel Nicolaus
$293
Hold
6.92%
Upside
Reiterated
02/21/25
Insulet (PODD) Receives a Hold from Stifel Nicolaus
Canaccord Genuity
$304→$324
Buy
18.23%
Upside
Reiterated
02/21/25
Insulet price target raised to $324 from $304 at CanaccordInsulet price target raised to $324 from $304 at Canaccord
Morgan Stanley
$317→$325
Buy
18.60%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)
Piper Sandler
$285→$310
Buy
13.12%
Upside
Reiterated
02/21/25
Insulet price target raised to $310 from $285 at Piper SandlerInsulet price target raised to $310 from $285 at Piper Sandler
Best Analysts Covering Insulet
Which Analyst Should I Follow If I Want to Buy PODD and Sell After:
1 Month
xxx
Success Rate
13/18 ratings generated profit
Average Return
+5.01%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +5.01% per trade.
3 Months
xxx
Success Rate
14/15 ratings generated profit
Average Return
+13.38%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +13.38% per trade.
1 Year
Success Rate
13/15 ratings generated profit
Average Return
+29.61%
reiterated a buy rating 23 days ago
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +29.61% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+71.47%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +71.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PODD Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
22
27
28
28
25
Hold
2
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
29
30
29
26
Each month's total comprises the sum of three months' worth of ratings.
PODD Financial Forecast
PODD Stock Forecast FAQ
What is PODD’s average 12-month price target, according to analysts?
Based on analyst ratings, Insulet’s 12-month average price target is $326.07.
What is PODD’s upside potential, based on the analysts’ average price target?
Insulet has 18.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PODD a Buy, Sell or Hold?
Insulet has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Insulet’s price target?
The average price target for Insulet is $326.07. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $355.00 ,the lowest forecast is $293.00. The average price target represents 18.99% Increase from the current price of $274.04.
The highest analyst price target is $355.00 ,the lowest forecast is $293.00. The average price target represents 18.99% Increase from the current price of $274.04.
What do analysts say about Insulet?
Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of PODD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.